AstraZeneca commissioned CRA to investigate the economic and societal burden associated with Acute Coronary Syndromes (ACS). Our Life Sciences specialists analyzed occurrences of ACS in the United Kingdom, treatment cost of ACS in the United Kingdom, economic cost of ACS, and the total burden of disease associated with ACS. This short paper represents a summary of the full report.
Asembia AXS25: Navigating the Evolving Landscape of GLP-1 Medications
Davis discussed the transition from obesity-specific opt-in benefits to more standard coverage. She expects that payers will need to handle a wider range of...